What We Learned From Q1 Pharma Earnings Season
Understand key dynamics and trends in this Scrip webinar
Executive Summary
With US drug pricing pressures and generic and biosimilar competition weighing on big pharma, new launches and brisk business in China have been providing a silver lining. Scrip writers analyze the industry landscape in light of the first-quarter results.